← Back to All US Stocks

CVRx, Inc. (CVRX) Stock Fundamental Analysis & AI Rating 2026

CVRX Nasdaq Surgical & Medical Instruments & Apparatus DE CIK: 0001235912
Updated This Month • Analysis: Mar 23, 2026 • SEC Data: 2025-12-31
Combined AI Rating
SELL
85% Confidence
STRONG AGREEMENT
SELL
85% Conf
SELL
85% Conf

📊 CVRX Key Takeaways

Revenue: $56.7M
Net Margin: -94.1%
Free Cash Flow: $-40.8M
Current Ratio: 7.63x
Debt/Equity: 1.26x
EPS: $-2.04
AI Rating: SELL with 85% confidence
CVRx, Inc. (CVRX) receives a SELL rating with 85% confidence from our AI fundamental analysis based on SEC 10-K filings. With revenue of $56.7M, net profit margin of -94.1%, and return on equity (ROE) of -135.6%, CVRx, Inc. demonstrates mixed fundamentals in the Healthcare sector. Below is our complete CVRX stock analysis for 2026.

Is CVRx, Inc. (CVRX) a Good Investment?

Claude

CVRx exhibits severe operational losses despite strong gross margins, indicating fundamental business model challenges beyond cost of goods sold. The company is heavily cash-dependent with negative free cash flow of -$40.8M and operating losses of -$51.3M, creating a runway concern even with substantial cash reserves of $75.7M. Revenue growth of 10.4% YoY is insufficient to justify the magnitude of operating losses and negative unit economics.

ChatGPT

CVRx shows a strong gross margin profile and double-digit revenue growth, which suggests the core product economics are attractive. However, those positives are overwhelmed by extremely weak operating leverage, with operating and net losses near revenue scale, deeply negative free cash flow, and poor returns on capital. The balance sheet still has meaningful cash, but the current burn rate and leverage leave limited room for execution missteps unless revenue growth accelerates materially and losses narrow.

Why Buy CVRx, Inc. Stock? CVRX Key Strengths

Claude
  • + Exceptional gross margin of 85.3% demonstrates strong pricing power and product-market fit at the manufacturing level
  • + Robust cash position of $75.7M provides runway to reach profitability, reducing near-term liquidity risk
  • + Double-digit revenue growth of 10.4% YoY shows market adoption and demand for core products
ChatGPT
  • + High gross margin of 85.3% indicates favorable unit economics and pricing power
  • + Revenue grew 10.4% year over year, showing ongoing commercial adoption
  • + Strong liquidity ratios and $75.71M of cash provide near-term operating flexibility

CVRX Stock Risks: CVRx, Inc. Investment Risks

Claude
  • ! Severe operating losses of -$51.3M with -90.5% operating margin indicate substantial costs in R&D, SG&A, or operations that are not scaling with revenue
  • ! Negative free cash flow of -$40.8M at current revenue levels means the business consumes cash even with positive gross profit, questioning path to sustainability
  • ! Cash burn rate of approximately -$40M+ annually combined with $49.5M long-term debt load suggests 1.5-2 year runway before cash depletion absent profitability inflection
ChatGPT
  • ! Operating margin of -90.5% and net margin of -94.1% show the business remains far from self-sustaining
  • ! Free cash flow of -$40.75M versus $75.71M cash implies a short runway if burn does not improve
  • ! Debt/equity of 1.26x and negative interest coverage indicate meaningful balance-sheet and financing risk

Key Metrics to Watch

Claude
  • * Path to operating profitability and timeline to positive operating income
  • * Operating expense rationalization as a percentage of revenue
  • * Cash burn rate trend and months of runway remaining
  • * Gross profit dollar growth relative to operating loss reduction
ChatGPT
  • * Revenue growth relative to operating expense growth
  • * Quarterly free cash flow burn and ending cash balance

CVRx, Inc. (CVRX) Financial Metrics & Key Ratios

Revenue
$56.7M
Net Income
$-53.3M
EPS (Diluted)
$-2.04
Free Cash Flow
$-40.8M
Total Assets
$104.8M
Cash Position
$75.7M

💡 AI Analyst Insight

Strong liquidity with a 7.63x current ratio provides a solid financial cushion.

CVRX Profit Margin, ROE & Profitability Analysis

Gross Margin 85.3%
Operating Margin -90.5%
Net Margin -94.1%
ROE -135.6%
ROA -50.9%
FCF Margin -71.9%

CVRX vs Healthcare Sector: How CVRx, Inc. Compares

How CVRx, Inc. compares to Healthcare sector averages

Net Margin
CVRX -94.1%
vs
Sector Avg 12.0%
CVRX Sector
ROE
CVRX -135.6%
vs
Sector Avg 15.0%
CVRX Sector
Current Ratio
CVRX 7.6x
vs
Sector Avg 2.0x
CVRX Sector
Debt/Equity
CVRX 1.3x
vs
Sector Avg 0.6x
CVRX Sector

Sector benchmarks are approximate industry averages. Actual sector performance may vary.

Is CVRx, Inc. Stock Overvalued? CVRX Valuation Analysis 2026

Based on fundamental analysis, CVRx, Inc. shows some fundamental concerns relative to the Healthcare sector in 2026.

Return on Equity
-135.6%
Sector avg: 15%
Net Profit Margin
-94.1%
Sector avg: 12%
Revenue Growth
N/A
Year-over-year
Debt/Equity
1.26x
Sector avg: 0.6x

Note: This is a fundamental analysis based on SEC filings. For P/E ratio, price targets, and market-based valuation, consult financial data providers. This is not investment advice.

CVRx, Inc. Balance Sheet: CVRX Debt, Cash & Liquidity

Current Ratio
7.63x
Quick Ratio
6.72x
Debt/Equity
1.26x
Debt/Assets
62.5%
Interest Coverage
-53.40x
Long-term Debt
$49.5M

CVRX Revenue & Earnings Growth: 5-Year Financial Trend

CVRX 5-year financial data: Year 2021: Revenue $13.0M, Net Income -$14.1M, EPS N/A. Year 2022: Revenue $22.5M, Net Income -$43.1M, EPS $-4.16. Year 2023: Revenue $39.3M, Net Income -$41.4M, EPS $-2.02. Year 2024: Revenue $51.3M, Net Income -$41.2M, EPS $-1.99. Year 2025: Revenue $56.7M, Net Income -$60.0M, EPS $-2.65.
Revenue
Net Income
EPS (right axis)

5-Year Trend Summary: CVRx, Inc.'s revenue has grown significantly by 335% over the 5-year period, indicating strong business expansion. The most recent EPS of $-2.65 indicates the company is currently unprofitable.

CVRX Revenue Growth, EPS Growth & YoY Performance

Revenue Growth
N/A
Year-over-year
Net Income Growth
N/A
Year-over-year
EPS Growth
N/A
Earnings per share
FCF Margin
-71.9%
Free cash flow / Revenue

CVRX Quarterly Earnings & Performance

Quarterly financial performance data for CVRx, Inc. including revenue, net income, and earnings per share.
Quarter Revenue Net Income EPS
Q3 2025 $13.4M -$12.9M $-0.49
Q2 2025 $11.8M -$14.0M $-0.57
Q1 2025 $10.8M -$13.8M $-0.53
Q3 2024 $10.5M -$9.0M $-0.43
Q2 2024 $9.5M -$11.7M $-0.56
Q1 2024 $8.0M -$11.4M $-0.55
Q3 2023 $6.2M -$9.0M $-0.43
Q2 2023 $5.0M -$11.1M $-0.54

Data sourced from SEC EDGAR 10-Q quarterly filings. Figures may represent quarterly or cumulative values.

CVRx, Inc. Dividends, Buybacks & Capital Allocation

Operating Cash Flow
-$40.2M
Cash generated from operations
Capital Expenditures
$580.0K
Investment in assets
Dividends
None
No dividend program

CVRX SEC Filings: Latest 10-K & 10-Q Analysis

Access official SEC EDGAR filings for CVRx, Inc. (CIK: 0001235912)

📋 Recent SEC Filings

Date Form Document Action
Apr 13, 2026 8-K tm2611335d1_8k.htm View →
Mar 16, 2026 4 xslF345X05/form4-03162026_080309.xml View →
Mar 4, 2026 4 xslF345X05/form4-03042026_090343.xml View →
Mar 3, 2026 4 xslF345X05/form4-03032026_110335.xml View →
Mar 3, 2026 4 xslF345X05/form4-03032026_110358.xml View →

Frequently Asked Questions about CVRX

What is the AI rating for CVRX?

CVRx, Inc. (CVRX) has a Combined AI Rating of SELL from Claude (SELL) and ChatGPT (SELL) with 85% combined confidence, based on fundamental analysis of SEC EDGAR filings.

What are CVRX's key strengths?

Claude: Exceptional gross margin of 85.3% demonstrates strong pricing power and product-market fit at the manufacturing level. Robust cash position of $75.7M provides runway to reach profitability, reducing near-term liquidity risk. ChatGPT: High gross margin of 85.3% indicates favorable unit economics and pricing power. Revenue grew 10.4% year over year, showing ongoing commercial adoption.

What are the risks of investing in CVRX?

Claude: Severe operating losses of -$51.3M with -90.5% operating margin indicate substantial costs in R&D, SG&A, or operations that are not scaling with revenue. Negative free cash flow of -$40.8M at current revenue levels means the business consumes cash even with positive gross profit, questioning path to sustainability. ChatGPT: Operating margin of -90.5% and net margin of -94.1% show the business remains far from self-sustaining. Free cash flow of -$40.75M versus $75.71M cash implies a short runway if burn does not improve.

What is CVRX's revenue and growth?

CVRx, Inc. reported revenue of $56.7M.

Does CVRX pay dividends?

CVRx, Inc. does not currently pay dividends.

Where can I find CVRX SEC filings?

Official SEC filings for CVRx, Inc. (CIK: 0001235912) including 10-K, 10-Q, and 8-K reports are available on SEC EDGAR.

What is CVRX's EPS?

CVRx, Inc. has a diluted EPS of $-2.04.

How is the AI analysis conducted?

Two independent AI systems — Claude (Anthropic) and ChatGPT (OpenAI) — analyze SEC EDGAR filings including 10-K annual reports and 10-Q quarterly reports. Each AI evaluates financial health, profitability ratios, balance sheet strength, and growth metrics. The combined rating reflects both perspectives for balanced insights.

Is CVRX a good stock to buy right now?

Based on our AI fundamental analysis in April 2026, CVRx, Inc. has a SELL rating with 85% confidence. Review the strengths and risks sections above before making a decision. This is not investment advice.

Is CVRX stock overvalued or undervalued?

Valuation metrics for CVRX: ROE of -135.6% (sector avg: 15%), net margin of -94.1% (sector avg: 12%). Compare these metrics with sector averages to assess valuation.

Should I buy CVRX stock in 2026?

Our dual AI analysis gives CVRx, Inc. a combined SELL rating for 2026. Revenue is data pending, with profitability at or below sector average. Always conduct your own research.

What is CVRX's free cash flow?

CVRx, Inc.'s operating cash flow is $-40.2M, with capital expenditures of $580.0K. FCF margin is -71.9%.

How does CVRX compare to other Healthcare stocks?

Vs Healthcare sector averages: Net margin -94.1% (avg: 12%), ROE -135.6% (avg: 15%), current ratio 7.63 (avg: 2).

Top Rated Stocks
NSSC 92% MLI 92% MELI 92% MDXG 92% MANH 92% INVA 92% GGG 92% GCT 92% FTNT 92% FSLR 92%
Sector: All Healthcare Stocks →
Disclaimer: This analysis is generated by Claude AI (Anthropic) and ChatGPT (OpenAI) based on publicly available SEC EDGAR filings. It does not include stock price data and should not be considered financial advice. All fundamental data is sourced from SEC public domain filings. Always conduct your own research and consult with a qualified financial advisor before making investment decisions.
Data Source: SEC EDGAR | Analysis Date: Mar 23, 2026 | Data as of: 2025-12-31 | Powered by Claude AI